Advertisement
Free access | 10.1172/JCI107076
Department of Medicine, Case Western Reserve University School of Medicine, and University Hospitals of Cleveland, Cleveland Ohio 44106
Find articles by Bennett, B. in: JCI | PubMed | Google Scholar
Department of Medicine, Case Western Reserve University School of Medicine, and University Hospitals of Cleveland, Cleveland Ohio 44106
Find articles by Ratnoff, O. in: JCI | PubMed | Google Scholar
Published October 1, 1972 - More info
Antihemophilic factor (AHF, factor VIII) levels were measured by a standard coagulation method and by an immunologic technique before and after infusion of AHF concentrates into patients with classic hemophilia. After infusion of AHF concentrates, the half-life of the AHF procoagulant (i.e., clot-promoting) activity varied from 12 to 14 hr, whereas that of the antigen ranged from 24 to 40 hr. The half-life of the antigen was similar in patients with and without circulating anticoagulants to AHF. The data are compatible with the suggestion that the antigen may be carried on a precursor molecule which the patient with hemophilia produces but cannot convert to the functional clot-promoting agent. Other explanations of the observations are, however, recognized.
Click on an image below to see the page. View PDF of the complete article